Dario A. Paggiarino - Feb 9, 2023 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Medical Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Feb 9, 2023
Transactions value $
-$15,612
Form type
4
Date filed
2/13/2023, 04:07 PM
Previous filing
Jan 10, 2023
Next filing
Jun 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +4.97K +26.63% $0.00 23.6K Feb 9, 2023 Direct
transaction EYPT Common Stock Options Exercise $0 +5.83K +24.7% $0.00 29.5K Feb 9, 2023 Direct
transaction EYPT Common Stock Tax liability -$8.43K -2.02K -6.87% $4.17 27.4K Feb 9, 2023 Direct F1
transaction EYPT Common Stock Tax liability -$7.18K -1.72K -6.28% $4.17 25.7K Feb 9, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -5.83K -33.33% $0.00 11.7K Feb 9, 2023 Common Stock 5.83K $0.00 Direct F2
transaction EYPT Restricted Stock Units Options Exercise $0 -4.97K -50% $0.00 4.97K Feb 9, 2023 Common Stock 4.97K $0.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units.
F2 The restricted stock units vest in three ratable annual installments beginning February 9, 2023.
F3 The restricted stock units vest in three ratable annual installments beginning February 9, 2022.